Hepatic apolipoprotein B synthesis in copper-deficient rats  by Nassir, Fatiha et al.
Volume 322, number 1, 33-36 FEBS 12386 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
May 1993 
Hepatic apolipoprotein B synthesis in copper-deficient rats 
Fatiha Nassir”, Andrzej Mazuf, Colette Strougneb, Elyett Gueuxa and Yves Rayssiguier” 
aLaboratoire des Maladies Mktaboliques, INRA, Theix, 63122 St. Gtkes Charnpanelle, France and bLaboratoire de Physiologie de 
la Nutrition, Universitk Paris Sud, 91405 Orsay C&dex, France 
Received 9 March 1993 
The present study was designed to examine if induction of apolipoprotein B synthesis is associated with hypercholesterolemia in copper-deficient 
rats. This hypercholesterolemia mainly resides in an increase in the HDL-1 and LDL and is associated with a significant increase in plasma apoB 
concentration. Liver apoB mRNA levels were not significantly modified in deficient animals as compared to control rats. Studies on liver 
apolipoprotein synthesis indicated that apoBlO0 synthesis was increased in deficient animals whereas apoB48 synthesis was unchanged. Thus, it 
appears that the increase in apoB synthesis in the liver of copper-deficient rats occurs at the posttranscriptional level. The selective increase in 
apoBlO0 synthesis indicates the possible impact of this deficiency on the editing of apoB. An increase in apoBlO0 synthesis by the liver in 
copper-deficient rats may significantly contribute to the increase in plasma concentration of LDL. 
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1. INTRODUCTION ing the mechanism responsible for hyperlipemia associ- 
ated with copper deficiency. 
Recent findings provided considerable information 
on the influence of copper deficiency on lipid metabo- 
lism and the cardiovascular system [1,2]. Copper defi- 
ciency has been demonstrated to induce hyper- 
cholesterolemia nd causes changes in lipoprotein con- 
centration and composition [2-4]. In copper-deficiency, 
increase in plasma lipid and apolipoprotein contents 
resides mostly in HDL for the rat model, whereas in 
rabbits and humans this increase is associated mainly 
with LDL [ 1,2]. Available evidence suggests that hyper- 
cholesterolemia in copper-deficient rats may be the re- 
sult of an increased rate of cholesterol synthesis in the 
liver [2,5]. ApoB is an obligatory component of lipopro- 
teins synthesized by the liver and serves as recognition 
marker for the uptake of LDL by the apoB, -E receptors 
[6]. An increased apoB synthesis is expected to accom- 
pany the elevated cholesterol synthesis in order to main- 
tain an enhanced lipoprotein secretion. However, at 
present there is no direct evidence available to support 
the proposed induction of apolipoprotein synthesis by 
copper deficiency [2]. The present study was then de- 
signed to examine apoB synthesis for better understand- 
2. MATERIALS AND METHODS 
2.1. Animals and diets 
Weanling male Wistar rats (Iffa-Credo, L’Arbresle, France) were 
divided at random into copper-deficient and control groups. Rats were 
housed in wire-bottomed cages in a temperature-controlled room 
(22°C) with 12 h light-dark cycle and were pair-fed the appropriate 
diets for 6 weeks. The semi-purified iets containing (g/kg) casein 200, 
sucrose 650, corn oil 50, alphacel 50, or-methionine 3, choline bitar- 
trate 2, modified AIN- mineral mix 35, AIN 76A vitamin mix 10 
(ICN Biomedicals, Orsay, France). Cupric carbonate was omitted 
from the AIN- mineral mix in the copper-deficient diet. The copper 
concentrations of diet were 0.4 mg/kg (deficient) and 6 mg/kg (con- 
trol). Fed animals were anesthetized with sodium pentobarbital 
(40 mg/kg body weight i.p.) and then killed. Blood was collected into 
tubes containing EDTA and plasma was obtained by low-speed cen- 
trifugation (2,000 x g). Hematocrit was determined by centrifugation 
in a capillary tube system to obtain packed cells. 
2.2. Plasma analyses 
Triglycerides (Biotrol, Paris, France) and cholesterol (BioMerieux, 
Charnonnieres-les-Bains, France) were determined in plasma by enzy- 
matic procedures. Noncompetitive ELISA was used to measure apoB 
in plasma as described previously [7j. 
2.3. ApoB distribution in lrpoprotein fractions 
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Lipoprotein fractions were separated from plasma by continuous 
gradient ultracentrifugation i  a L8.70 Beckman centrifuge using a 
SW41 rotor as described previously [8]. A control tube containing only 
saline solutions was used to determine the density of fractions by 
refractometry. 22 fractions were collected from the meniscus of the 
tubes and total protein content in these fractions was assayed [9]. 
Aliquots of isolated fractions were submitted to PAGE-SDS on 5% 
acrylamide slab gel. The samples were subsequently electroblotted to 
nitrocellulose membranes (Hybond-C Super, Amersham, Bucks, UK). 
The distribution of apoB in lipoprotein fractions was shown by im- 
munostaining of apoB with sheep anti-rat apoB immunoserum and 
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peroxidase-labeled rabbit anti-sheep IgG (Sigma, L’Isle d’Abeau, 
France). 
2.4. RNA extraction and analysis 
Total cellular RNA was isolated from liver tissue using the guani- 
dinium/phenol/chloroform ethod according to Chomczynski and 
Sacchi [lo]. RNA was quantitated by measuring the absorbance at 260 
nm. Its integrity was assessed by agarose-gel lectrophoresis and visu- 
alization of 18s and 28s ribosomal RNAs by ethidium bromide stain- 
ing. Aliquots of total RNA were subjected to quantification of mRNA 
content by dot-blot analysis on nylon filters. Hybridization of immo- 
bilized RNA to cDNA probes for rat apoB (kindly provided by P. 
Cardot) and for mouse 18s (kindly provided by G. Veyssiere) labeled 
with [a-32P]dATP (Amersham) and washing was conducted as previ- 
ously described [1 11. The filters were blotted dry, and autoradiography 
was performed with intensifying screens at -7O’C. Quantification of 
specific mRNA was performed by densitometric analysis of the hy- 
bridization signal using a laser densitometer (Ultroscan XL, LKB, 
Sweden). Relative abundance of the apoB mRNA was expressed as 
the apoB/l8S mRNA ratio. 
2.5. Determination of hepatic apoB synthesis rates 
ApoB synthesis rates were determined in the liver of copper-ade- 
quate and copper-deficient rats as described by Baum et al. [12]. 
Animals were anesthetized with sodium pentobarbital and received 1 .O 
mCi L-[4,5-‘Hlleucine (specific activity 5.29 TBq/mmol; Amersham) 
via intraportal vein injection. Following a 15 min incubation period, 
animals were exsanguinated and the liver perfused in situ for 15 min 
with 100 ml of ice-cold PBS, 20 mM leucine containing freshly added 
PMSF (1 mM final concentration). Livers were quickly removed, 
weighed, and portions removed for analysis of apoB synthesis rates. 
Pieces were taken from all lobes for homogenization in PBS, 1% 
T&on, 2 mM leucine containing freshly added protease inhibitors 
(PMSF 1 mM, benzamidine 1 mM, N-p-tosyl-L-lysine chloromethyl 
ketone 25 PM, leupeptin 100 PM, EDTA 5 mM, aprotinin 450 PM, 
pepstatin 2 PM). A 225,000 x g supernatant was prepared and stored 
at -80°C prior to immunoprecipitation. Aliquots of homogenates 
were saved for measurement of total protein concentration and TCA- 
insoluble radioactivity. Quantitative immunoprecipitation of apoB 
was performed using monospecific polyclonal rabbit antiserum di- 
rected against rat apoB. Immunoprecipitation was conducted using a 
buffer with the following final composition: 100 mM NaCl, 50 mM 
LiCl, 5 mM EDTA, 50 mM Tris, 0.02% sodium azide, 0.5% Triton, 
0.5% sodium deoxycholate, an 0.05% SDS, at pH 7.4 and washed S. 
aureus cells (Pansorbin, Calbiochem, San Diego, CA). Immune com- 
plex was washed extensively and separated on denaturing SDS-PAGE 
disc gels (4% acrylamide). Gels were sliced and radioactivity was 
determined by liquid scintillation spectrometry (Kontron, St-Quentin- 
en-Yvelines, France) following addition of 3% Protosol-Econofluor 
(NEN, Boston, MA) to gel slices. Data are expressed as percent of 
total (TCA-insoluble) radioactivity. 
2.6. Statistics 
Values are given as means + S.E.M. Data were analyzed by Stu- 
dent’s t-test. 
3. RESULTS 
As shown in Table I, copper-deficient rats had lower 
body weights and higher relative liver and heart weights 
than control rats. Reduced plasma copper concentra- 
tions and reduced hematocrit values were found in cop- 
per-deficient animals. Plasma cholesterol and apoB 
concentrations were significantly greater in copper-defi- 
cient rats as compared to control animals. 
Density gradient ultracentrifugation study indicates 
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Table I 
Body and organ weights, and biochemical data of control and copper- 
deficient rats 
Body weight (g) 
Relative liver weight 
Control 
289 f 3 
Copper-deficient 
242 f 8** 
WOO g) 
Relative heart weight 
3.8 f 0.1 6.1 f 0.2+* 
WOO g) 
Hematocrit (volume fraction) 
Plasma copper @mol/l) 
Plasma triglycerides 
0.33 f 0.01 0.73 f 0.05** 
0.41 f 0.02 0.17 * 0.03** 
14.6 f 0.50 0.60 f 0.08** 
(mmol/l) 
Plasma total cholesterol 
0.70 + 0.09 0.98 f 0.15 
(mmol@ 1.55 f 0.06 1.98 f O.ll* 
Plasma apoB (mg/l) 65 +4 115 + 6** 
Results are mean f S.E.M. of 12 rats per group. *PC 0.01; 
**p c 0.001. 
marked alteration in the distribution of lipoproteins in 
copper-deficient rats as compared to control ones (Fig. 
1). Hypercholesterolemia ssociated with copper defi- 
ciency leads to an increase in HDL and LDL protein 
concentrations. As shown by immunoblot analysis of 
isolated lipoprotein fractions (Fig. 2), the increase in 
plasma apoB levels in copper-deficient rats mostly re- 
sults from an increase in apoBlO0 in LDL. 
There was no difference in total protein synthesis in 
both groups as shown by t3H]leucine incorporation into 
total TCA-insoluble material (control 118 + 10 cpm@g 
protein (n = 6); copper deficient 110 f 13 cpm&g pro- 
tein (n = 6) P > 0.05). Studies of apoB synthesis in the 
liver have shown (Table II) that there is a marked (dou- 
bling) increase in hepatic apoBlO0 synthesis without 
modification in apoB48 synthesis in copper-deficient 
rats as compared to control ones. Copper-deficiency did 
not modify apoB mRNA level in the liver (Table II). 
4. DISCUSSION 
Several measurements are indicators of dietary cop- 
per deficiency in addition to the reduced plasma copper 
concentration, such as decreased body weight gain, in- 
creased heart- and liver-to-body weight ratio and lower 
hematocrit [ 131. Copper deficiency increases blood 
cholesterol more consistently than it increases blood 
triglyceride concentrations [ 1,2]. This hypercholesterol- 
emia is mainly the result of an increase in the concentra- 
tion of HDL and in particular in HDLl subfraction 
[2,4]. Additionally, as shown in the present work by 
density gradient ultracentrifugation study and im- 
munoblot analysis of isolated fractions, the increase in 
plasma apoB concentration in copper-deficient rats 
mostly results from an increase in LDL concentration. 
The present study demonstrates that increased apoB 
synthesis in the liver accompanies copper deficiency in- 
duced hyperlipemia. Moreover, specific increase in 
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Fig. 1. (A) Protein distribution in lipoprotein fractions separated by density gradient ultracentrifugation from control (n = 6) or copper-deficient 
rats (n = 5). Results are expressed as mean f S.E.M.; P < 0.01; P -C 0.001. (B) Immunoblot analysis of apolipoprotein B distribution in lipoprotein 
fractions separated by density gradient ultracentrifugation from control or copper-deficient rats. 
apoBlO0 synthesis uggests that this may contribute to the liver is enhanced in copper-deficient rats. Thus, the 
the increase in plasma concentration of LDL containing induction of apoB synthesis by copper deficiency may 
essentially apoB as apolipoprotein. Increases in the syn- be related to this increase in production of fatty acids 
thetic rates of fatty acids and an accelerated eftlux of and cholesterol in the liver in order to both assemble 
newly synthesized cholesterol ester from the liver to the and secrete triglyceride-rich lipoproteins. 
plasma have been observed in copper deficiency [2]. Control of apoB synthesis and secretion can occur at 
These observations uggest hat lipoprotein secretion by number of levels involving changes in apoB mRNA 
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Table II 
Apolipoprotein B synthesis and mRNA level in the liver of control and 
copper-deficient rats 
Control Copper-deficient 
ApoBlOO synthesis 
(8 of total protein synthesis) 0.20 + 0.03 0.41 r 0.04* 
ApoB48 synthesis 
(8 of total protein synthesis) 0.15 + 0.03 0.21 f 0.04 
ApoB mRNA level 
(% of control) 100 f 11 82 f 12 
Results are mean + S.E.M. of 6 rats per group. *P c 0.01. 
abundance, apoB mRNA editing, and through modifi- 
cations in intracellular degradation of newly synthe- 
sized apoB [6,14]. In agreement with our previous study 
[ 111 we have shown that copper deficiency is not associ- 
ated with modification in apoB mRNA in the liver. 
Thus it appears that copper deficiency affects apoB syn- 
thesis at the post-transcriptional level. Unlike the hu- 
mans synthesizing only one form of apoB (apoBlOO), 
rat liver synthesizes two forms: apoBlO0 and apoB48. 
The mechanism accounting for the synthesis of these 
two forms of apoB involves mRNA editing [15]. It has 
been shown that the relative proportions of apoBlO0 
and apoB48 made by the liver are not constant and may 
be physiologically regulated [12]. Recent studies have 
demonstrated that hepatic apoB mRNA editing in the 
rat is regulated developmentally and by various nutri- 
tional and hormonal factors [12,16]. It has been shown 
that apoB mRNA abundance and apoB editing are reg- 
ulated dramatically by the food deprivation and refeed- 
ing [12]. As a precautionary measure, in our study we 
equalized dietary intake by daily pair-feeding in attempt 
to counteract the possible effect of differences in food 
intake on the studied parameters between control and 
deficient animals. In summary, it appears that the in- 
crease in apoB synthesis in the liver of copper-deficient 
rats occurs at the posttranscriptional level. The selective 
increase in apoBlO0 synthesis indicates the possible im- 
pact of this deficiency on the editing of apoB. An in- 
crease in apoBlO0 synthesis by the liver in copper-defi- 
cient rats may significantly contribute to the increase in 
plasma concentration of LDL, containing essentially 
apoB 100 as apolipoprotein. 
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